# EDGAR Filing Document

**Accession Number:** 0001839140
**File Stem:** 0001213900-26-070415
**Filing Date:** 2026-6
**Character Count:** 5447
**Document Hash:** 7b6214c293cef825925ad71d7e26e0b8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-070415.hdr.sgml**: 20260622

**ACCESSION NUMBER**: 0001213900-26-070415

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260616

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**FILED AS OF DATE**: 20260622

**DATE AS OF CHANGE**: 20260622

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Revium Rx.
- **CENTRAL INDEX KEY:** 0001839140
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 844516676
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 333-284934
- **FILM NUMBER:** 261105253

**BUSINESS ADDRESS:**
- **STREET 1:** C/O ABOUDI LEGAL GROUP PLLC, 745 5TH AVE
- **STREET 2:** SUITE 500
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10151
- **BUSINESS PHONE:** 6467684285

**MAIL ADDRESS:**
- **STREET 1:** C/O ABOUDI LEGAL GROUP PLLC, 745 5TH AVE
- **STREET 2:** SUITE 500
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10151

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Revium Recovery, Inc.
- **DATE OF NAME CHANGE:** 20210105

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**Form 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934** 

Date of Report (Date of earliest event reported): June 16, 2026

---

| |
|:---|
| **REVIUM Rx.** |
| (Exact Name of Registrant as Specified in its Charter) |

---

---

| | | |
|:---|:---|:---|
| **Nevada** | **333-284934** | **84-4516676** |
| (State or other jurisdiction<br> of incorporation) | (Commission File Number) | (I.R.S. Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **Azrieli Business Center 89, Medinat Hayehudim Street<br> Herzliya, Israel** | **10017** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **<u>1 800 519-1687</u>**

---

| |
|:---|
| **n/a** |
| (Former name or former address, if changed since last report) |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| N/A | N/A | N/A |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.**

<u>Resignation of Ms. Inna Martin from her positions as Director, Chief Operating Officer and President</u>

On June 16, 2026, Ms. Inna Martin resigned from her position as a member of the Board of Directors of Revium Rx. ("we", "us", "our", "Revium" or the "Company") and as Chief Operating Officer and President thereof, effective immediately. Ms. Martin's resignation was in light of certain differences in expectations between her and the Company. At the time of her resignation, Ms. Martin did not hold positions on any committees of the Board of Directors.

In connection with Ms. Martin's departure, the Company's subsidiary, Revium Rx Ltd. ("Revium Ltd.") and Ms. Martin entered into a Termination Agreement and Waiver (the "Separation Agreement"), effective as of June 16, 2026, pursuant to which Ms. Martin's employment and consultancy engagement with Revium Ltd. will terminate on September 10, 2026. Additionally, the exercise period for Ms. Martin's vested stock options to purchase up to 2,440,000 shares of the Company's common stock has been extended until September 30, 2028. Ms. Martin's shares and options are subject to certain sale restrictions as contained in the Separation Agreement.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  | **REVIUM Rx.** | **REVIUM Rx.** | **REVIUM Rx.** |
| June 22, 2026 | By: | /s/ Amir Avraham | /s/ Amir Avraham |
|  |  | Name: | Amir Avraham |
|  |  | Title: | Chief Executive Officer |

---